In addition, a recent study reported that not only the PD-L1 status but also the PD-L2 status was useful for predicting the clinical response to anti-PD1 immunotherapy in head and neck carcinoma45, suggesting that the status of tumor PD-L2 may have clinical implications for anti-PD1 immunotherapy. Here, PDCD1LG2 is linked to neoplasm.